Anthraquinones derived from soil actinomycetes combat multidrug-resistant Staphylococcus aureus

Area of Science:

• Microbiology
• Pharmacology
• Biochemistry

Background:

• The rise of multidrug-resistant Staphylococcus aureus (MRSA) presents a significant global health and food safety challenge.
• Novel therapeutic strategies are urgently needed to combat MRSA infections and contamination.

Purpose of the Study:

• To evaluate the antibacterial potential of anthraquinone compound 13394-2 against MRSA.
• To elucidate the mechanisms of action and assess the safety and efficacy of compound 13394-2.

Main Methods:

• In vitro susceptibility testing (MIC), time-kill assays, biofilm assays.
• Mechanistic studies including membrane integrity, reactive oxygen species (ROS) generation, ATP depletion assays.
• Transcriptomic analysis, computational modeling, biophysical experiments, in vivo animal models, and food/surface contamination models.

Main Results:

• Compound 13394-2 demonstrated potent in vitro activity against MRSA (MIC as low as 0.25 μg/mL) with rapid bactericidal effects.
• Mechanisms involve membrane disruption, ROS accumulation, ATP depletion, and interference with protein, energy, and fatty acid metabolism, targeting FabF.
• Compound 13394-2 showed low cytotoxicity, good in vivo safety, efficacy in animal infection models, and effective elimination of MRSA in contamination models.

Conclusions:

• Anthraquinone compound 13394-2 exhibits significant potential as a novel therapeutic agent against multidrug-resistant Staphylococcus aureus.
• Its broad efficacy extends to treating infections and mitigating environmental contamination, supporting its development as a new antibiotic.
• The findings highlight anthraquinones as a promising class of compounds for addressing antibiotic resistance and public health threats.